Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

AEON Biopharma, Inc. AEON

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.24
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership
52.94%

Capital & Financial Ratios

Market Cap
12.19
Revenue
—
Net Income
(54.62)
Free Cash Flow
(13.64)
Net Debt
(3.43)
Current Ratio
0.54
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.00
P/B ratio
0.00
Past 5Y EPS Growth
—
This Y EPS Growth
89.37%
Next Y EPS Growth
15.08%
Next 5Y EPS Growth
67.15%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2026 ‡‡‡‡‡
2025 ‡‡‡‡‡
2024 ‡‡‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 5.16 0.01 3.01 3.43
Receivables — — — —
Inventory — — — —
Other — — — —
6.22 1.59 3.40 3.99
2023 2024 2025 Q'26
Payables 3.39 5.91 0.94 2.70
ST’ Debt — — — —
Other 3.59 3.60 1.66 —
13.05 14.15 6.90 7.34
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — —
Cash Flow — — ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2.64) (3.70) — —
—
’25 (7.91) (2.09) (2.60) (4.71)
(17.31)
’24 (8.60) (8.12) (2.95) (0.62)
(20.29)
’23 (11.06) (10.08) (15.66) (11.02)
(47.82)
’22 (0.41) (0.16) (26.56) (8.45)
(35.58)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2.64) (3.70) — —
—
’25 (7.91) (2.09) (2.60) (4.71)
(17.31)
’24 (8.60) (8.12) (2.95) (0.62)
(20.29)
’23 (11.06) (10.08) (15.66) (11.02)
(47.82)
’22 (0.41) (0.16) (26.86) (8.46)
(35.89)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.29) (0.02) — —
—
’25 2.28 (0.60) (0.39) (3.72)
(3.95)
’24 (0.08) 303.60 (11.51) (51.08)
72.93
’22 0.08 0.05 0.05 0.11
0.29
’21 0.18 (0.12) 0.16 0.01
0.24

Target Price Range

High
‡‡‡‡
‡‡‡
Average
‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — — — — 242.64 36.14 0.38 — — —
Low Price
— — — — — — — 1,056.96 1,236.24 42.48 — — —
High Price
— — — — — ‡‡‡ 3 10 5 8 — — —
Employees
— — — — — ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — — — — — — — — — — — —
Gross Margin
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (52.56) (384.63) 42.01 (39.22) — — —
EBT
— — — — ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ — — ‡‡‡‡‡ ‡‡‡‡‡ (52.56) (384.63) 42.01 (39.22) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — — — — — 0.07 0.10 0.10 0.08 — — —
Depreciation
— — — — ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 20.81 (116.97) 77.74 (3.95) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — — — ‡‡‡ ‡‡‡‡‡ (18.44) (92.68) (37.58) (1.74) — — —
Cash Flow/Sh
— — — — ‡‡‡ ‡‡‡ (0.16) 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — — — ‡‡‡ ‡‡‡‡‡ (18.60) (92.68) (37.58) (1.74) — — —
Free CF/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (140.11) (296.60) (52.91) (5.55) ‡‡‡‡ — —
Book Value/Sh
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 1.93 0.52 0.54 9.92 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡‡ —
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — — — — — — —
EV/FCF
— — — — — ‡‡‡‡‡ (35.58) (47.82) (20.29) (17.31) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — — — — — (0.31) — — 0.00 ‡‡‡‡‡ — —
Capex
— — — — — ‡‡‡‡‡ (35.89) (47.82) (20.29) (17.31) ‡‡‡‡‡ — —
FCF
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (72.74) (6.83) (12.56) (3.50) — — —
Working Cap'
— — — — ‡‡‡‡‡ — 131.29 — 11.69 34.60 — — —
Total Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 121.55 (5.16) 11.68 31.59 — — —
Net Debt
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (270.41) (153.04) (28.57) (55.03) — — —
Sh' Equity
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (36.53%) (4,365.11%) 841.19% (901.45%) — — —
ROA
— — — — ‡‡‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
— — — — ‡‡‡ ‡‡‡‡‡ 36.58% 181.66% (46.26%) 93.84% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

AEON Biopharma (NYSE: AEON), a clinical-stage biotech targeting botulinum toxin therapies like ABP-450 for chronic migraine, exemplifies high-volatility biotech investing with zero revenue through 2024 but explosive projections of $4.41 billion in 2025 and $4.58 billion in 2026—implying blockbuster potential in a $7+ billion market if Phase 3 data and FDA approval materialize mid-2025. Net income swung from a -$385 million nadir in 2023 (driven by trial costs) to +$42 million in 2024, with EPS rebounding from -$117 to +$78, signaling cost controls and milestones amid lean operations (employee count halved to 5).

Balance sheet risks loom with deeply negative equity (-$29 million in 2024) and shares outstanding surging 4,700% via dilution, fueling 85%+ stock drawdowns despite profitability. Yet, insider buys (170,000 shares at ~$0.50 in May 2025), 58% FCF burn improvement, and analyst targets implying 420% mean upside (PS near 0 on future revenue) scream undervaluation. Catalysts like partnerships and commercialization could drive 5x returns, mirroring peers, but trial misses risk 90% wipeouts—positioning for asymmetry in a rebounding biotech sector.

Read full commentary →

AEON Biopharma, Inc. (AEON) Latest News

News by impact score

Fine-tune

9 Sep

4 , 8:00 AM
AEON Biopharma reports positive pilot forced degradation results confirming analytical comparability of ABP-450 to BOTOX®. Positive forced degradation data bolsters ABP-450 comparability to BOTOX and strengthens regulatory and market prospects.

24 Aug

3 , 8:00 AM
AEON Biopharma designates former FDA neuroscience leader Paul Lee, M.D., Ph.D. as acting chief regulatory officer. Former FDA neuroscience leader in acting CRO role may aid regulatory filings without altering core strategy.

19 Aug

3 , 8:00 AM
AEON Biopharma reports expanded structural data confirming molecular similarity of ABP-450 to BOTOX®. Similarity data bolsters ABP-450 validation and market positioning against established neurotoxins.

12 Aug

3 , 4:15 PM
AEON Biopharma reported second quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates typically affect short-term stock sentiment and valuation but rarely alter long-term company trajectory.

3 GlobeNewswire, 4:05 PM
AEON Biopharma, Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and providing updates on corporate developments. The company continues to focus on advancing its product pipeline and strategic initiatives aimed at enhancing market presence and operational efficiency. The financial results and corporate updates indicate moderate influences on AEON's performance and market positioning.

14 Jul

3 , 8:00 AM
AEON Biopharma priced an upsized $13.75 million public offering accompanied by milestone warrants that could deliver additional future funding. The capital raise supplies operating cash and optional milestone proceeds that moderately strengthen AEON's financial runway.

4 Jun

3 GlobeNewswire, 7:00 AM
AEON Biopharma will present data showing structural and functional comparability of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society. Data presentation on ABP-450 supports development visibility but carries no immediate regulatory or revenue impact.

14 May

4 GlobeNewswire, 4:05 PM
AEON Biopharma, Inc. reported its first quarter 2025 financial results, highlighting progress in its biosimilar development program for ABP-450 under the 351(k) regulatory pathway, aiming for FDA approval covering all BOTOX indications. The company appointed Rob Bancroft as President and CEO, who brings over 25 years of experience in the life sciences industry. AEON has $10.4 million in cash, expected to fund operations through Q4 2025, and plans a BPD Type 2a meeting with the FDA in the second half of 2025. The company is also working to regain compliance with NYSE American listing standards by August 2026. The advancement of the biosimilar program and leadership changes are significant strategic moves that could alter AEON's market position and investor sentiment.

3 GlobeNewswire, 4:05 PM
AEON Biopharma reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates influence AEON's financial performance and investor sentiment.

3 Apr

4 GlobeNewswire, 4:05 PM
AEON Biopharma, Inc. (AEON) received an additional notice from NYSE American regarding noncompliance with continued listing standards. Additional NYSE American listing deficiency notice increases delisting risk, significantly threatening stock liquidity, investor confidence, and market performance.

30 Mar

4 GlobeNewswire, 4:05 PM
AEON Biopharma reported full-year 2025 financial results alongside positive comparative analytical results and favorable FDA feedback for its ABP-450 biosimilar program. Positive FDA feedback and analytical results for ABP-450 biosimilar represent a significant regulatory milestone advancing AEON's pipeline and market prospects.

26 Mar

4 TipRanks, 8:17 AM
AEON Biopharma announced FDA feedback following a Type 2a meeting, providing guidance on clinical development plans. FDA Type 2a meeting feedback represents a key regulatory milestone that could accelerate AEON's product development and boost investor confidence.

25 Mar

4 GlobeNewswire, 8:00 AM
AEON Biopharma announces FDA feedback following Type 2a meeting for ABP-450 biosimilar program. FDA feedback from Type 2a meeting advances ABP-450 biosimilar development, potentially accelerating regulatory approval and market entry for AEON.

9 Mar

3 GlobeNewswire, 4:05 PM
AEON Biopharma, Inc. (AEON) appointed John Bencich as Chief Financial Officer to lead financial strategy amid ongoing biopharma developments. CFO appointment influences financial oversight and investor confidence but lacks transformative elements like product approvals.

21 Jan

4 GlobeNewswirePharma VoiceMT NewswiresMarketBeatMT NewswiresMT NewswiresClinical Trials ArenaGuruFocus.com, 4:05 PM
AEON Biopharma, Inc. has reported a successful Type 2a meeting with the FDA regarding its treatment for BPD, which is a significant step in the regulatory process. Additionally, shareholders have approved transactions that took place in November, further solidifying the company's strategic direction and financial stability. The FDA meeting and shareholder approval are significant developments that could enhance AEON's market position and future growth prospects.

14 Jan

3 Simply Wall St., 2:37 AM
An intrinsic calculation for Aeon Co. (M) Bhd. suggests that the company is undervalued by 42%. This analysis indicates potential for growth and investment opportunities, highlighting the disparity between market price and intrinsic value. The undervaluation suggests a moderate influence on market sentiment and investment interest, but does not guarantee immediate significant changes in performance.

15 Dec

4 GlobeNewswireMT NewswiresMT NewswiresMT NewswiresInsider MonkeyMT Newswires, 4:05 PM
AEON Biopharma, Inc. has executed an exchange agreement with Daewoong Pharmaceutical Co., Ltd., which involves the exchange of shares and the potential for collaboration on product development. This agreement is expected to enhance AEON's strategic position and may lead to advancements in its therapeutic offerings. The partnership aims to leverage Daewoong's expertise in biopharmaceuticals to accelerate AEON's growth and innovation in the market. The exchange agreement with Daewoong is a significant strategic move that could enhance AEON's product development and market position.

14 Dec

3 Simply Wall St., 9:14 PM
AEON Biopharma, Inc. (AEON) has experienced a significant decline in its stock value, with investors facing a 24% loss over the past year. This downturn raises concerns about the company's financial health and market position, potentially affecting investor sentiment and future performance. A 24% loss in stock value indicates moderate concerns about financial performance and market sentiment.

20 Nov

4 GlobeNewswire, 8:30 AM
AEON Biopharma, Inc. announced the first closing of a PIPE investment, which is expected to enhance its financial position. Additionally, the company provided an update regarding the scheduling of its FDA Type 2a meeting, a crucial step in its regulatory process for product development. The PIPE investment and FDA meeting scheduling are significant developments that could impact AEON's financial health and regulatory progress.

14 Nov

4 GlobeNewswire, 8:30 AM
AEON Biopharma, Inc. reported its third quarter 2025 results, highlighting positive biosimilarity data for ABP-450. The company is strategically positioning itself for continued growth in the biopharmaceutical market, focusing on expanding its product offerings and enhancing its competitive edge. Positive biosimilarity data and strategic growth initiatives are likely to significantly impact AEON's future performance and market positioning.

13 Nov

4 GlobeNewswire, 8:30 AM
AEON Biopharma, Inc. (AEON) announced positive biosimilarity results, demonstrating an identical amino acid sequence and highly similar functional analysis data for its product. These findings support the company's efforts in developing biosimilar therapies, potentially enhancing its competitive position in the biopharmaceutical market. Positive biosimilarity results are likely to significantly impact AEON's future performance and market positioning.

1 Oct

4 GlobeNewswire, 8:00 AM
AEON Biopharma, Inc. announced a meeting with the FDA scheduled for November 19 to discuss the Biologics License Application (BLA) for its product ABP-450, aimed at treating patients with chronic pain. This meeting is a critical step in the regulatory process, potentially influencing the product's approval timeline and market entry. The FDA meeting is a significant regulatory milestone that could impact the company's future product launch and market positioning.

28 Sep

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 8:02 PM
Aeon Co. (M) Bhd. has experienced recent stock weakness, raising questions about its financial prospects. Despite the downturn, analysts suggest that the company's fundamentals remain solid, indicating that the market may be undervaluing its potential. Investors are encouraged to consider the long-term outlook as the company navigates current challenges. The stock's recent weakness could moderately influence investor sentiment and financial performance, but the company's fundamentals suggest a balanced outlook.

7 Aug

3 , 2:07 AM
Investors may be undervaluing Aeon Co. (M) Bhd. by 39%, according to recent analyses. The company's financial metrics suggest that its stock price does not reflect its intrinsic value, leading to potential investment opportunities. Analysts are urging a closer examination of Aeon's market position and growth prospects, which could indicate a favorable outlook for investors. The undervaluation suggests a moderately noticeable influence on investor sentiment and potential financial performance.

7 Jul

3 Simply Wall St., 3:17 AM
Aeon Co. (M) Bhd. (KLSE:AEON) has seen a 41% increase in share price over the last five years, outperforming the market's 4.1% return. However, recent gains have been modest, with a 5.5% return including dividends. The company's earnings per share (EPS) grew at 11% annually, indicating a cautious market sentiment despite solid performance. The total shareholder return (TSR) over five years was 66%, primarily due to dividends. In the past year, the TSR was 5.5%, falling short of the five-year average. Aeon (M) Bhd shows one warning sign in investment analysis, suggesting potential concerns for investors. Moderate EPS growth and a solid TSR indicate stable performance, but recent returns suggest caution among investors.

19 May

3 GlobeNewswire, 4:05 PM
AEON Biopharma, Inc. announced that Rob Bancroft, President and CEO, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on May 21st. AEON is focused on developing its proprietary botulinum toxin complex, ABP-450, for various medical conditions. ABP-450 is the same botulinum toxin complex marketed for cosmetic use as Jeuveau by Evolus and is approved as a biosimilar in Mexico and India. AEON holds exclusive rights for therapeutic indications in several regions, including the U.S. and EU. The presentation at a significant conference may enhance investor sentiment and visibility but does not guarantee immediate substantial changes in the company's trajectory.

25 Apr

4 , 4:05 PM
AEON Biopharma, Inc. has received notification from NYSE American that its plan to regain compliance with listing standards has been accepted. The company has until August 3, 2026, to meet the minimum market capitalization and stockholders' equity requirements. During this period, AEON will be subject to periodic reviews by NYSE American. Failure to comply could lead to delisting. AEON focuses on developing a botulinum toxin complex for various therapeutic indications, with its product ABP-450 already approved for cosmetic use in some markets. Regaining compliance with NYSE listing standards is critical for AEON's future market performance and investor confidence.

21 Apr

4 , 4:05 PM
AEON Biopharma, Inc. announced the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, who has over 25 years of experience in the life sciences industry, will also join AEON's Board of Directors. He aims to advance the company's ABP-450 program along the 351(k) biosimilar regulatory pathway, potentially offering a clinically comparable alternative to BOTOX. Former CEO Marc Forth will remain on the Board. The company anticipates announcing results from its FDA meeting regarding ABP-450 in the second half of 2025. The appointment of a seasoned CEO and the focus on advancing a biosimilar product are significant strategic moves that could alter AEON's market position.

27 Mar

3 , 4:05 PM
AEON Biopharma, Inc. announced a transition in its CEO position, with the current CEO stepping down and a new leader set to take over. This change is part of the company's strategic efforts to enhance its leadership and drive future growth. The board expressed confidence in the new CEO's ability to lead AEON towards its goals. Leadership changes can moderately influence company direction and market perception.

24 Mar

3 , 4:05 PM
AEON Biopharma, Inc. reported its financial results for the fourth quarter and full year of 2024, highlighting key metrics and providing a corporate update. The company outlined its strategic initiatives and future plans, emphasizing growth prospects and operational developments. The financial results and corporate update indicate moderate influence on AEON's future performance and market sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us